The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Romano Sarah since 2017.
This trader's CIK number is 1697536.
At the time of last reporting, Romano Sarah was the Chief Financial Officer of Entero Therapeutics, Inc.. (stock ticker symbol ENTO).
Also see all insider trading activities at Entero Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | EYEG | 0 | $0 | 19,750 | $4,673 | 0 | $0 |
| 2018 | EYEG | 62,500 | $0 | 0 | $0 | 0 | $0 |
| 2017 | EYEG | 30,000 | $10,000 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ENTO | 0 | $0 | 727 | $465 | 0 | $0 |
| 2024 | ENTO | 0 | $0 | 2,390 | $7,159 | 0 | $0 |
| 2023 | ENTO | 0 | $0 | 5,628 | $8,467 | 0 | $0 |
1. Kiora Pharmaceuticals Inc (EYEG)
2. Entero Therapeutics, Inc. (ENTO)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-07-11 | EYEG | Sale | 6,583 | .24 | 1,586 |
| 2019-07-12 | EYEG | Sale | 6,583 | .24 | 1,553 |
| 2019-07-15 | EYEG | Sale | 6,584 | .23 | 1,534 |
| 2018-04-17 | EYEG | Buy | 62,500 | .00 | 0 |
| 2017-08-15 | EYEG | Buy | 10,000 | 1.00 | 10,000 |
| 2017-06-14 | EYEG | Buy | 20,000 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-06 | ENTO | Sale | 727 | .64 | 465 |
| 2024-10-09 | ENTO | Sale | 476 | .45 | 212 |
| 2024-07-02 | ENTO | Sale | 621 | 1.07 | 664 |
| 2024-04-01 | FWBI | Sale | 75 | 4.23 | 317 |
| 2024-03-15 | FWBI | Sale | 1,120 | 4.96 | 5,555 |
| 2024-01-12 | FWBI | Sale | 98 | 4.20 | 411 |
| 2023-10-04 | FWBI | Sale | 1,676 | .29 | 486 |
| 2023-07-03 | FWBI | Sale | 1,977 | 1.54 | 3,044 |
| 2023-04-03 | FWBI | Sale | 1,975 | 2.50 | 4,937 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Romano Sarah (Chief Financial Officer of Entero Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.